Literature DB >> 32822210

The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart.

Lydia E Matesic1, Lisa A Freeburg2, Laura B Snyder2, Lauren-Ashley Duncan1, Amber Moore2, Paige E Perreault2, Kia N Zellars2, Edie C Goldsmith3, Francis G Spinale2.   

Abstract

Ubiquitylation is a key event that regulates protein turnover, and induction of the ubiquitin ligase E3 WWP1 has been associated with age. Left ventricular hypertrophy (LVH) commonly occurs as a function of age and can cause heart failure (HF) with a preserved ejection fraction (EF; HFpEF). We hypothesized that overexpression (O/E) of WWP1 in the heart would cause LVH as well as functional and structural changes consistent with the aging HFpEF phenotype. Global WWP1 O/E was achieved in mice (n = 11) and echocardiography (40 MHz) performed to measure LV mass, EF, Doppler velocities (early E, late/atrial A), myocardial relaxation (E'), and isovolumetric relaxation time (IVRT) at 4, 6, and 8 wk. Age-matched wild-type animals (n = 15) were included as referent controls. LV EF was identical (60 ± 1 vs. 60 ± 1%, P > 0.90) with no difference in LV mass (67 ± 3 vs. 75 ± 5, P > 0.25) at 4 wk. However, at 8 wk of age, LV mass increased over twofold, E/A fell (impaired passive filling), and E/E' was lower and IVRT prolonged (impaired LV relaxation) - all P < 0.05. Collagen percent area increased by over twofold and fibrillar collagen expression (RT-PCR) over 1.5-fold (P < 0.05) with WWP1 O/E. WWP1 with an anti-WWP1 antibody could be identified in isolated cardiac fibroblasts, with WWP1 increased over twofold in O/E fibroblasts (P < 0.05). Inducing WWP1 expression caused LVH and preserved systolic function but impaired diastolic dysfunction, consistent with the HFpEF phenotype. Targeting the WWP1 pathway may be a novel therapeutic target for this intractable form of HF associated with aging.NEW & NOTEWORTHY Heart failure (HF) with a preserved ejection fraction (HFpEF) is a growing cause of HF and commonly afflicts the elderly. Milestones for HFpEF include diastolic dysfunction and an abnormal extracelluar matrix (ECM). The ubiquitin ligases, such as WWP1, change with aging and regulate critical protein turnover/stability processes, such as the ECM. The present study demonstrated that induction of WWP1 in mice induced LV hypertrophy, diastolic dysfunction, and ECM accumulation, consistent with the HFpEF phenotype, and thus may identify a new therapeutic pathway.

Entities:  

Keywords:  aging; cardiac hypertrophy; diastolic dysfunction; heart failure; ventricular remodeling

Mesh:

Substances:

Year:  2020        PMID: 32822210      PMCID: PMC7717125          DOI: 10.1152/ajpheart.00620.2019

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  39 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

Authors:  S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

Review 3.  Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review.

Authors:  Evelien E S van Riet; Arno W Hoes; Kim P Wagenaar; Alexander Limburg; Marcel A J Landman; Frans H Rutten
Journal:  Eur J Heart Fail       Date:  2016-01-04       Impact factor: 15.534

4.  E3 ubiquitin ligase, WWP1, interacts with AMPKα2 and down-regulates its expression in skeletal muscle C2C12 cells.

Authors:  Jung Ok Lee; Soo Kyung Lee; Nami Kim; Ji Hae Kim; Ga Young You; Ji Wook Moon; Sha Jie; Su Jin Kim; Yong Woo Lee; Ho Jin Kang; Yongchul Lim; Sun Hwa Park; Hyeon Soo Kim
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

Review 5.  Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease.

Authors:  Amanda B Pullen; Jeevan Kumar Jadapalli; Boutayna Rhourri-Frih; Ganesh V Halade
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

6.  Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats.

Authors:  R Doi; T Masuyama; K Yamamoto; Y Doi; T Mano; Y Sakata; K Ono; T Kuzuya; S Hirota; T Koyama; T Miwa; M Hori
Journal:  J Hypertens       Date:  2000-01       Impact factor: 4.844

Review 7.  Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.

Authors:  Ravi B Patel; Sanjiv J Shah; Gregg C Fonarow; Javed Butler; Muthiah Vaduganathan
Journal:  Curr Heart Fail Rep       Date:  2017-08

Review 8.  Analyzing left ventricular function in mice with Doppler echocardiography.

Authors:  Abdallah Fayssoil; François Tournoux
Journal:  Heart Fail Rev       Date:  2013-07       Impact factor: 4.214

9.  The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.

Authors:  C Chen; Z Zhou; R Liu; Y Li; P B Azmi; A K Seth
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

10.  Guidelines for measuring cardiac physiology in mice.

Authors:  Merry L Lindsey; Zamaneh Kassiri; Jitka A I Virag; Lisandra E de Castro Brás; Marielle Scherrer-Crosbie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-05       Impact factor: 4.733

View more
  1 in total

Review 1.  From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited.

Authors:  Walter J Paulus; Michael R Zile
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.